Novartis: Proteinuria trials
The registry lists 12 Proteinuria studies with Novartis as lead sponsor. 7 are open to participants now and 1 have results posted.
Phase 2 2Phase 3 5Phase 4 2No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNot yet recruitingNCT07850752Phase 3
- A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 GlomerulopathyRecruitingNCT07416162
- CHART-C3G/CLNP023B12011Not yet recruitingNCT07331259
- A Study to Assess the Effects of Zigakibart on IgA Nephropathy.RecruitingNCT07146906Phase 2
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANRecruitingNCT06994845Phase 3
- Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNRecruitingNCT05755386Phase 3
- Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.RecruitingNCT04817618Phase 3
- Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsCompletedNCT04578834Phase 3Results posted
- Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VTerminatedNCT05268289Phase 2
- Human Urine Sample Collection for Alport Nephropathy Biomarker StudiesTerminatedNCT01602835
- To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes MellitusCompletedNCT00550095Phase 4
- Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes MellitusCompletedNCT00241085Phase 4